in this issue
Regions :: North America :: U.S.
BMS Extends Lonza Contract
8:17 AM MDT | July 26, 2007 | Alex Scott
Bristol-Myers Squibb (BMS) says it has agreed to extend a supply agreement with Lonza, in which Lonza will manufacture BMS’s biologic rheumatoid arthritis drug Orencia until 2014. Orencia was approved by FDA in 2005 and launched in the U.S. in February 2006. The product generated sales of $32 million in the final quarter of 2006. Lonza will produce the product at its Portsmouth, NH facility. Separately, Lonza says it has granted UCB a non-exclusive license to its glutamine synthetase (GS) gene expression system for manufacturing therapeutic recombinant...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee